Partner David Rosen was quoted in an article published in FDA Week on April 18, 2014, titled “FDA Argument For 5-Year NCE Exclusivity Denial Unfounded, Gilead Says.” The article explains the appeal by Gilead Sciences, a manufacturer of one of three drug-drug combination products, asking the Federal Drug Administration (FDA) to reconsider its decision to prospectively change its new chemical entities policies for other combination drugs. Rosen was quoted saying, “One thing you can appreciate is FDA is very considered in its decision-making process at this time.”
People
Related News
12 May 2025
In the News
Judith Waltz Comments on Provider Settlement After Self-Disclosure
Foley & Lardner LLP partner Judith Waltz commented on a recent settlement by a provider with the U.S. Department of Health and Human Services Office of Inspector General (OIG) in the Report on Medicare Compliance article, "After Self-Disclosure, Provider Settles Case Over Failure to Report, Return Overpayments."
12 May 2025
In the News
Foley's Digital Infrastructure Arrivals Featured Across Legal Press
Foley & Lardner LLP partners Daniel Farris and Joe McClendon are featured in legal press for their arrival to the firm.
07 May 2025
In the News
Foley Attorneys Featured in Q&A on CPSC Oversight of Cosmetics Industry
Foley & Lardner LLP attorneys Erik Swanholt, Kristin McGaver, and Mikaela Mitchum are featured in a Cosmetics Design Q&A on what industry brands need to know regarding oversight from the U.S. Consumer Product Safety Commission.